P 16 - Transition Therapeutics
Latest Information Update: 15 Mar 2006
At a glance
- Originator Transition Therapeutics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 15 Mar 2006 No development reported - Preclinical for Multiple sclerosis in Canada (unspecified route)
- 24 Sep 2002 Preclinical trials in Multiple sclerosis in Canada (unspecified route)